SlateStone Wealth’s Novartis NVS Stock Holding History

SlateStone Wealth’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,055	Closed	-$666K	–	175
2020 Q4	$666K	Hold	7,055	–	–	0.17%	102
2020 Q3	$614K	Hold	7,055	–	–	0.13%	117
2020 Q2	$616K	Sell	7,055 -165	-2%	-$14.2K	0.14%	114
2020 Q1	$595K	Sell	7,220 -515	-7%	-$45.9K	0.17%	106
2019 Q4	$732K	Buy	7,735 +255	+3%	+$22.9K	0.17%	108
2019 Q3	$650K	Buy	7,480 +800	+12%	+$71.8K	0.19%	92
2019 Q2	$610K	Sell	6,680 -886	-12%	-$75K	0.17%	102
2019 Q1	$652K	Sell	7,566 -10,402	-58%	-$835K	0.2%	88
2018 Q4	$1.38M	Buy	+17,968	New	+$1.4M	0.64%	42

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SlateStone Wealth's NVS Position: Q1 2021 in Review

SlateStone Wealth sold out of Novartis (NVS) in Q1 2021, closing a stake of 7,055 shares — an estimated $666K sold.

SlateStone Wealth first reported a position in NVS in Q4 2018 and held it in 9 quarters. The position peaked at $1.38M in Q4 2018. 1,136 funds tracked by Wall St. Rank hold NVS as of Q1 2021.

SlateStone Wealth reported no remaining Novartis position as of Q1 2021 after selling out during the quarter.
SlateStone Wealth sold 7,055 Novartis shares in Q1 2021, an estimated $666K.
SlateStone Wealth first reported a position in Novartis in Q4 2018 and held it in 9 quarters.
SlateStone Wealth's Novartis position peaked at $1.38M in Q4 2018.
1,136 funds tracked by Wall St. Rank held Novartis as of Q1 2021.

Based on SlateStone Wealth's 13F filing for Q1 2021, filed 19 Apr 2021.